CircRNAs are novel therapeutic targets for various diseases, and they can regulate cellular pathways and modulate diverse diseases.[30] The structural properties of circRNAs include their presence in body fluids such as plasma and saliva, which allows their application as potential clinical biomarkers.[31] In this study, clinical data revealed that circ‐PIAS1‐5 expression in the blood was decreased in patients with atherosclerosis complicated by HHcy and was significantly correlated with Hcy and HDL concentrations but not with TC, TG, LDL, urea, Crea, ALB, AST, or ALT concentrations. The gene discussed is ALB; the disease is atherosclerosis.